FUROSCIX Drug Patent Profile

Which patents cover Furoscix, and when can generic versions of Furoscix launch?

Furoscix is a drug marketed by Scpharmaceuticals and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-four patent family members in fifteen countries.

The generic ingredient in FUROSCIX is furosemide. There are twenty-two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the furosemide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Furoscix

A generic version of FUROSCIX was approved as furosemide by ESJAY PHARMA on July 27^th, 1982.

Summary for FUROSCIX

International Patents:	24
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	137
Clinical Trials:	2
Patent Applications:	3,390
Drug Prices:	Drug price information for FUROSCIX
What excipients (inactive ingredients) are in FUROSCIX?	FUROSCIX excipients list
DailyMed Link:	FUROSCIX at DailyMed

See drug prices for FUROSCIX

Recent Clinical Trials for FUROSCIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Texas Southwestern Medical Center	Phase 2
scPharmaceuticals, Inc.	Phase 2
scPharmaceuticals, Inc.	Phase 1

See all FUROSCIX clinical trials

Pharmacology for FUROSCIX

Drug Class	Loop Diuretic
Physiological Effect	Increased Diuresis at Loop of Henle

US Patents and Regulatory Information for FUROSCIX

FUROSCIX is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	11,433,044
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	10,272,064		Y
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	9,884,039
Scpharmaceuticals	FUROSCIX	furosemide	SOLUTION;SUBCUTANEOUS	209988-001	Oct 7, 2022		RX	Yes	Yes	12,370,168		Y

International Patents for FUROSCIX

See the table below for patents covering FUROSCIX around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	367165	FORMULACIONES FARMACÉUTICAS PARA ADMINISTRACIÓN SUBCUTÁNEA DE FUROSEMIDA. (PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE.)
South Korea	20210075211	퓨로세마이드의 피하 투여용 약학 제형 (PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE)
European Patent Office	2981258	FORMULATIONS PHARMACEUTIQUES POUR L'ADMINISTRATION SOUS-CUTANÉE DE FUROSÉMIDE (PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE)
Mexico	2015014064	FORMULACIONES FARMACEUTICAS PARA ADMINISTRACION SUBCUTANEA DE FUROSEMIDA. (PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE.)

Market Dynamics and Financial Trajectory for FUROSCIX

Last updated: January 9, 2026

Executive Summary

FUROSCIX, a novel, sustained-release formulation of intravenous (IV) furosemide administered via subcutaneous (SC) infusion, addresses chronic volume overload in heart failure (HF) patients. Approved by the FDA in August 2022, it aims to revolutionize diuretic therapy by providing outpatient, self-administered treatment, potentially disrupting traditional hospital-based management. This report analyzes the evolving market landscape, competitive positioning, reimbursement environment, and projected financial trajectory for FUROSCIX.

---

What Are the Key Market Drivers for FUROSCIX?

1. Growing Burden of Heart Failure

• Prevalence & Incidence: Over 6.5 million Americans live with HF, projected to rise to 8 million by 2030 ([1]).
• Hospitalizations: Approximately 1 million annual hospitalizations due to HF exacerbations, incurring healthcare costs exceeding $40 billion annually ([2]).
• Rehospitalization Rates: Nearly 25% of patients are readmitted within 30 days, emphasizing need for better outpatient management ([3]).

2. Limitations of Current Diuretic Therapies

• Oral Furosemide: Variability in absorption and bioavailability leads to inconsistent diuresis ([4]).
• Intravenous Furosemide: Typically administered inpatient, requiring hospitalization, which increases costs and patients' quality-of-life burden.
• Home Diuretic Programs: Limited by infusion logistics and patient compliance.

3. Advantages of FUROSCIX

• Convenience: Subcutaneous delivery offers outpatient, self-administration potential.
• Consistent Dosing: Controlled release mitigates fluctuations seen with oral dosing.
• Reduced Hospitalizations: Early intervention may lower readmission rates ([5]).

---

How Is the Competitive Landscape Shaping Up?

1. Existing Therapeutic Alternatives

Product/Approach	Mode of Action	Use Case	Limitations
Oral Furosemide	Oral absorption	Outpatient diuresis	Variability; poor bioavailability in some patients
IV Loop Diuretics	Hospital-based IV	Acute decompensation	Inpatient-only; invasive
Continuous Home Infusion Devices	IV or SC, via infusion pumps	Outpatient management	Costly; invasive; compliance issues
Emerging SGLT2 Inhibitors	Oral, systemic	Chronic HF management	Indirect diuretic effect, not direct

2. FUROSCIX's Position in Market

Differentiator	Impact	Potential Barriers
Self-administration	Empowers outpatient care	Need for patient education & compliance
Sustained-release formulation	Stable diuretic effect	Manufacturing complexity & costs
Compatibility with existing care models	Seamless integration	Provider adoption inertia

3. Forecasted Market Penetration

• Initial Adoption: Targeted toward NYHA Class III-IV HF patients with recurrent hospitalizations.
• Long-term Adoption: Broader use in ambulatory settings, chronic HF management, and possibly other edematous conditions.

Projected market penetration estimates suggest 10-15% of the eligible HF outpatient population within the first 5 years post-launch.

---

What Are the Financial Outlooks and Revenue Projections?

1. Regulatory and Commercial Strategy

• Regulatory Status: FDA approval granted in August 2022.
• Pricing Strategy: Approximate list price at $300–$500 per dose, aligned with hospital outpatient infusion services ([6]).
• Distribution Channels: Hospital systems, specialty pharmacies, direct physician supply.

2. Revenue Model Assumptions

Parameter	Details	Source/Justification
Market Size (U.S.)	600,000 eligible HF patients	Based on prevalence data ([1])
Penetration Rate (Year 1)	2%	Conservative early adoption estimate
Price per Dose	$400 (avg.)	Market comparisons & reimbursement standards ([6])
Doses per Patient per Month	1–2	Dosing frequency for chronic HF management
Yearly Revenue	Calculated based on number of patients × doses × price	Model projection

Sample Year 1 Revenue Calculation:

• Patients: 12,000 (2% of 600,000)
• Doses per patient/year: 12 (monthly dosing)
• Revenue: 12,000 × 12 × $400 = $57.6 million

3. Growth Trajectory

Year	Market Penetration	Estimated Revenue	Notes
Year 1	2%	~$58M	Initial launch, early adopters
Year 3	10%	~$290M	Expanded clinical awareness & reimbursement coverage
Year 5	15%	~$435M	Broader use case, increased provider familiarity

Note: These figures are contingent upon FDA approval, P&T and reimbursement policies, and actual clinical outcomes.

---

How Will Reimbursement and Market Access Evolve?

1. Reimbursement Landscape

• Medicare & Medicaid: Likely coverage due to outpatient setting and hospital cost-offset benefits.
• Private Payers: Expected to adopt similar policies, contingent on clinical efficacy and cost savings.
• Coding & Billing: Potential for reliance on existing outpatient infusion codes with updates for SC delivery systems.

2. Market Access Challenges

• Demonstrating real-world cost savings.
• Provider education on use and benefits.
• Ensuring patient adherence and support.

3. Policy Trends Influencing Growth

• Shift Toward Outpatient HF Management: CMS initiatives favor home-based therapies ([7]).
• Value-Based Care Models: Incentivize interventions that reduce readmissions ([8]).

---

What Are the Key Financial Risks and Opportunities?

Risks

• Delayed/Reinforced Barriers: Slow provider adoption; reimbursement hurdles.
• Manufacturing Challenges: Scalability and cost control.
• Competitive Entry: New formulations or similar devices.

Opportunities

• Market Leadership: First-approved sustained-release SC furosemide.
• Cost Savings: Reducing hospital readmissions aligns with payer incentives.
• Broader Indications: Potential expansion to other edematous conditions like renal failure or liver cirrhosis.

---

How Does FUROSCIX Compare Globally?

Region	Regulatory Status	Market Potential	Challenges
Europe	Under review/approved	Similar HF burden, different reimbursement policies	Differing healthcare systems and protocols
Asia-Pacific	Early-stage	Growing HF prevalence	Infrastructure & provider training

---

Final Insights

Aspect	Status/Outlook
FDA Approval	Achieved August 2022
Market Potential	Significant, driven by HF prevalence and outpatient care shift
Revenue Trajectory	Projected to reach hundreds of millions within 5 years
Competitive Edge	First-in-class sustained-release SC diuretic
Risks	Adoption speed, reimbursement policies, manufacturing costs

---

Key Takeaways

• FUROSCIX's innovative delivery mechanism positions it favorably in the expanding outpatient HF management market.
• The product addresses critical gaps in current diuretic therapy, promising improved patient compliance and potential for reduced hospitalizations.
• Financial projections depend heavily on market penetration, payer acceptance, and clinical evidence of efficacy.
• Strategic positioning with payers and providers, coupled with ongoing clinical validation, will be critical to realizing revenue potential.
• Competitive pressures and policy shifts represent both challenges and avenues for growth.

---

FAQs

1. What differentiates FUROSCIX from traditional IV or oral furosemide therapies?

FUROSCIX offers sustained, subcutaneous delivery of furosemide, enabling outpatient self-administration, reducing variability associated with oral dosing, and potentially decreasing hospitalization rates.

2. What are the main reimbursement considerations for FUROSCIX?

Reimbursement will largely depend on outpatient infusion codes, value-based care incentives, and payer recognition of cost savings related to reduced hospitalizations. Early engagement with payers is essential.

3. How does FUROSCIX impact patient quality of life?

By facilitating outpatient treatment and reducing hospital visits, FUROSCIX aims to improve quality of life, especially for patients with recurrent HF exacerbations or mobility limitations.

4. What are the barriers to FUROSCIX’s market adoption?

Clinician awareness, patient adherence, reimbursement hurdles, manufacturing scalability, and competition from alternative therapies could slow uptake.

5. Could FUROSCIX be expanded to indications beyond heart failure?

Yes, potential exists for applications in other edematous conditions like kidney failure, liver cirrhosis, or postoperative fluid management, contingent upon clinical validation.

---

References

1. Roger VL. Epidemiology of Heart Failure. Circ Res. 2021;128(10):1421-1444.
2. Benjamin EJ, et al. Heart Disease and Stroke Statistics—2022 Update. Circulation. 2022;145(8):e153-e639.
3. Curtis LH, et al. The 30-day readmission rate for heart failure. J Am Heart Assoc. 2018;7(9):e009159.
4. Felker GM, et al. Oral versus intravenous diuretics. J Card Fail. 2009;15(10):846-855.
5. Cotter G, et al. The impact of early outpatient diuretic therapy. Eur J Heart Fail. 2019;21(8):985-993.
6. Industry estimates; pricing analysis based on market data.
7. CMS Outpatient & Home Health Policies, 2022.
8. Agency for Healthcare Research and Quality. Value-based care initiatives, 2021.

---

Disclaimer: This analysis reflects current available data and projected market trends; actual outcomes may vary based on regulatory decisions, clinical results, and market dynamics.